Loading patent…
AssigneeVir Biotechnology, Inc.
InventorsEric E. BRUENING, Klaus FRUEH, Louis PICKER, Bette T. KORBER, James THEILER, Emily MARSHALL
Estimating the term…
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.
An HIV-1 vaccine comprising one or more carriers and one or more population episensus antigens determined using the EpiGraph approach.
A polypeptide comprising one or more HIV-1 population episensus antigens determined using the EpiGraph approach, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of:
An HIV-1 vaccine comprising one or more carriers, a population episensus antigen determined using the EpiGraph approach, and one or more tailored antigens.
An HIV-1 vaccine comprising one or more carriers and one or more population episensus antigens or tailored antigens, wherein the population episensus antigen and the tailored antigen are determined using the EpiGraph method.
A polypeptide comprising one or more HIV-1 population episensus antigens or HIV-1 tailored antigens, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of:
A method of designing and producing an HIV-1 vaccine for a subject comprising:
A method of designing and producing an HIV-1 vaccine for a subject comprising:
A method of inducing an effector memory T cell response comprising:
Dependencies are inferred from the claim text.